Advertisement
COLL vs PCRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and PCRX is a Hold.
COLL's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for COLL moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 17 of the 24 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on COLL as a result. In 65 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where COLL advanced for three days, in 217 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 60 cases where COLL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COLL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
COLL broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for COLL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.396) is normal, around the industry mean (9.032). P/E Ratio (15.205) is within average values for comparable stocks, (-3.059). Projected Growth (PEG Ratio) (0.664) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.995) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. COLL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COLL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
PCRX in upward trend: price rose above 50-day moving average on October 07, 2026
PCRX moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PCRX as a result. In 61 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for PCRX just turned positive on October 07, 2026. Looking at past instances where PCRX's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
The 10-day moving average for PCRX crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in 215 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 124 of 188 cases where PCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PCRX broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.160) is normal, around the industry mean (9.012). P/E Ratio (104.057) is within average values for comparable stocks, (-3.044). Projected Growth (PEG Ratio) (0.684) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1.416) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
COLL | PCRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 93 | 100 | |
SMR RATING 1..100 | 50 | 88 | |
PRICE GROWTH RATING 1..100 | 64 | 35 | |
P/E GROWTH RATING 1..100 | 91 | 4 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COLL's Valuation (59) in the Pharmaceuticals Other industry is in the same range as PCRX (84). This means that COLL’s stock grew similarly to PCRX’s over the last 12 months.
COLL's Profit vs Risk Rating (93) in the Pharmaceuticals Other industry is in the same range as PCRX (100). This means that COLL’s stock grew similarly to PCRX’s over the last 12 months.
COLL's SMR Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for PCRX (88). This means that COLL’s stock grew somewhat faster than PCRX’s over the last 12 months.
PCRX's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as COLL (64). This means that PCRX’s stock grew similarly to COLL’s over the last 12 months.
PCRX's P/E Growth Rating (4) in the Pharmaceuticals Other industry is significantly better than the same rating for COLL (91). This means that PCRX’s stock grew significantly faster than COLL’s over the last 12 months.
| COLL | PCRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 73% |
| MACD ODDS (%) | N/A | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 72% |
| Advances ODDS (%) | 9 days ago 69% | 2 days ago 70% |
| Declines ODDS (%) | 12 days ago 70% | 19 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COLL’s FA Score shows that 0 FA rating(s) are green while PCRX’s FA Score has 1 green FA rating(s).
- COLL’s FA Score: 0 green, 5 red.
- PCRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COLL’s TA Score shows that 3 TA indicator(s) are bullish while PCRX’s TA Score has 7 bullish TA indicator(s).
- COLL’s TA Score: 3 bullish, 4 bearish.
- PCRX’s TA Score: 7 bullish, 3 bearish.
Price Growth
COLL (@Pharmaceuticals: Generic) experienced а -0.99% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was +0.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.73%. For the same industry, the average monthly price growth was -10.62%, and the average quarterly price growth was +7.84%.
Reported Earning Dates
COLL is expected to report earnings on Nov 05, 2026.
PCRX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.73% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
COLL and
Correlation & Price change
A.I.dvisor indicates that over the last year, COLL has been loosely correlated with EBS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then EBS could also see price increases.
| Ticker / NAME | Correlation To COLL | 1D Price Change % | ||
|---|---|---|---|---|
| COLL | 100% | -2.30% | ||
| EBS - COLL | 40% Loosely correlated | N/A | ||
| VTRS - COLL | 36% Loosely correlated | -2.60% | ||
| AMRX - COLL | 34% Loosely correlated | -0.49% | ||
| AMPH - COLL | 33% Loosely correlated | -3.46% | ||
| SNDL - COLL | 33% Loosely correlated | N/A | ||
More | ||||